-
Multiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy. J. Immunother. (IF 3.9) Pub Date : 2023-11-27 Eric Olsen,Steven A Svoboda,Marjorie Montanez-Wiscovich,Sami K Saikaly
Immune checkpoint inhibitors are increasingly being utilized for the treatment of advanced neoplastic disease and have been associated with wide-ranging cutaneous adverse effects. Though exceedingly rare, eruptive keratoacanthomas have been associated with the use of immune checkpoint inhibitors such as pembrolizumab and nivolumab, whose molecular target is the programmed cell death protein 1. Herein
-
Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report. J. Immunother. (IF 3.9) Pub Date : 2023-11-23 Yufu Lin,Yabo Chen,Shenggan Lin,Jingmei Zheng,Xiuping Zhang,Lu Gan
Gastric cancer is the most common type of gastrointestinal cancer in China which about 80% of patients are locally advanced or advanced when diagnosed. Surgery along brings high recurrence rate for locally advanced gastric cancer (LAGC), and neoadjuvant therapies are needed. The use of programmed cell death-1 (PD-1)/programmed death-ligand 1 inhibitor nowadays improved the disease-free survival for
-
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer. J. Immunother. (IF 3.9) Pub Date : 2023-11-22 Magdalena M Coman,Lajos Pusztai,Regina Hooley,Liva Andreveja,Leah Kim,Nikhil Joshi,Alexey Bersenev,Diane Krause,Tristen S Park
Adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes (TILs) have produced long-term response in metastatic cancers. TILs have traditionally been expanded from surgically resected specimens. Ultrasound-guided core needle biopsy (CNB) is an alternative method that avoids the morbidity of surgery and have added benefits which may include patients not amenable to surgery as well as the
-
A New Method for Constructing Macrophage-Associated Predictors of Treatment Efficacy Based on Single-Cell Sequencing Analysis. J. Immunother. (IF 3.9) Pub Date : 2023-11-20 Jianxiu Lin,Yang Ran,Tengfei Wu,Zishan Wang,Jinjin Zhao,Yun Tian
Tumor-associated macrophages (TAMs) are highly infiltrated in the tumor microenvironment (TME) of colorectal cancer (CRC) and play a vital role in CRC's development as well as prognosis. The required data were obtained from the Gene Expression Omnibus database and The Cancer Genome Atlas. Univariate Cox regression and least absolute shrinkage operator analyses were executed for model construction.
-
Effect of Concomitant Use of Proton Pump Inhibitors on Immunotherapy Clinical Response in Advanced Cancer Patients: Real-Life Setting. J. Immunother. (IF 3.9) Pub Date : 2023-11-06 Lorenzo Cantarelli,Fernando Gutiérrez Nicolás,Sara García Gil,Jose A Morales Barrios,Juana Oramas Rodriguez,Gloria J Nazco Casariego
The alteration of the gut microbiota mediated by proton pump inhibitor (PPI) drugs could be involved in the clinical response associated with immunotherapy [immunocheckpoint inhibitors (ICIs)] in cancer patients. Due to the current controversy in the scientific evidence, it has been proposed to evaluate the correlation between the concomitant use of PPIs and the effectiveness of immunotherapy in a
-
Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study. J. Immunother. (IF 3.9) Pub Date : 2023-11-06 Arjun A Raghavan,Sid Goutam,Grace Musto,Marc Geirnaert,Carrie Ye,Liam J O'Neil,Jeffrey Graham
Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, patients with pre-existing autoimmune diseases (PADs) have largely been excluded from clinical trials evaluating this drug class. This study evaluates the effectiveness and safety of ICI therapy in individuals with PAD in a real-world setting. A retrospective study of patients exposed to ICI therapy between 2012 and
-
Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy. J. Immunother. (IF 3.9) Pub Date : 2023-11-01 Ilit Turgeman,Anat Reiner Benaim,Stav Regev -Tsur,Shahar Turgeman,Mahmud Abu Amna,Omar Badran,Gil Bar-Sela
Metabolic pathways may regulate responses to cancer immunotherapy (IO). Due to its immunomodulatory properties, we sought to examine the association between serum vitamin B12 (VitB12) and survival in individuals with cancer treated with immune checkpoint inhibitors, compared with biological and chemotherapy. We collected data on patients with advanced cancer initiating intravenous antineoplastic treatment
-
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study). J. Immunother. (IF 3.9) Pub Date : 2023-10-09 Chantal Decroisette,Laurent Greillier,Hubert Curcio,Maurice Pérol,Charles Ricordel,Jean-Bernard Auliac,Lionel Falchero,Remi Veillon,Sabine Vieillot,Florian Guisier,Marie Marcq,Grégoire Justeau,Laurence Bigay-Game,Marie Bernardi,Hélène Doubre,Julian Pinsolle,Karim Amrane,Christos Chouaïd,Renaud Descourt
Outside clinical trials, few data are available on the effect of long-term first-line pembrolizumab in patients with advanced non-small-cell lung cancers with ≥50% of tumor cells expressing programmed cell death ligand 1 (PD-L1). This French, multicenter study included consecutive advanced patients with non-small-cell lung cancer given first-line pembrolizumab alone between May 2017 (authorization
-
Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model. J. Immunother. (IF 3.9) Pub Date : 2023-09-20 Vincent M D'Anniballe,Min-Nung Huang,Benjamin D Lueck,Lowell T Nicholson,Ian McFatridge,Michael D Gunn
Undifferentiated monocytes can be loaded with tumor antigens (Ag) and administered intravenously to induce antitumor cytotoxic T lymphocyte (CTL) responses. This vaccination strategy exploits an endogenous Ag cross-presentation pathway, where Ag-loaded monocytes (monocyte vaccines) transfer their Ag to resident splenic dendritic cells (DC), which then stimulate robust CD8 + CTL responses. In this study
-
Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report. J. Immunother. (IF 3.9) Pub Date : 2023-09-19 Viola Schön,Daniel Stocker,Christoph Jüngst,Reinhard Dummer,Egle Ramelyte
Immune checkpoint inhibitors have improved the treatment of many cancers. However, immune-related (IR) adverse events can limit their use. A rare but potentially severe IR adverse event is IR-cholangitis, which is mostly induced by anti-programmed cell death 1 (PD1) antibodies and is often corticosteroid-resistant. Consequently, immunosuppressive therapy is increased, which interferes with the antitumor
-
Laser Interstitial Thermal Therapy Induces Robust Local Immune Response for Newly Diagnosed Glioblastoma With Long-term Survival and Disease Control. J. Immunother. (IF 3.9) Pub Date : 2023-09-19 Jay S Chandar,Shovan Bhatia,Shreya Ingle,Mynor J Mendez Valdez,Dragan Maric,Deepa Seetharam,Jelisah F Desgraves,Vaidya Govindarajan,Lekhaj Daggubati,Martin Merenzon,Alexis Morell,Evan Luther,Ali G Saad,Ricardo J Komotar,Michael E Ivan,Ashish H Shah
Laser interstitial thermal therapy (LITT) is a minimally invasive neurosurgical technique used to ablate intra-axial brain tumors. The impact of LITT on the tumor microenvironment is scarcely reported. Nonablative LITT-induced hyperthermia (33-43˚C) increases intra-tumoral mutational burden and neoantigen production, promoting immunogenic cell death. To understand the local immune response post-LITT
-
Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review. J. Immunother. (IF 3.9) Pub Date : 2023-09-18 Yong Fan,Juan Zhao,Yue Mi,Zhening Zhang,Yan Geng,Liqun Zhou,Lin Shen,Zhuoli Zhang
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer, however, often with immune-related adverse events (irAEs). Adverse events involving the bladder were extremely rare with only few cases. Herein, we described a rare, recurrent cystitis associated with 2 programmed death 1 inhibitors (pembrolizumab and toripalimab) in 1 patient with advanced liver cancer. Cystitis
-
Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models. J. Immunother. (IF 3.9) Pub Date : 2023-08-15 Mei Yang,Tian Guan,Chun-Fa Chen,Li-Fang He,Hao-Ming Wu,Ren-Dong Zhang,Yun Li,Yan-Chun Lin,Haoyu Zeng,Jun-Dong Wu
The emergence of immunotherapy has introduced a promising, novel approach to cancer treatment. While multiple chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable clinical efficacy against leukemia, their effect on solid tumors has been limited. One potential option for treating solid tumors is the engineering of natural killer (NK) cells with CARs. Mesothelin (MSLN), a tumor
-
Surfaceome Profiling Suggests Potential of Anti-MUC1×EGFR Bispecific Antibody for Breast Cancer Targeted Therapy. J. Immunother. (IF 3.9) Pub Date : 2023-07-24 Mona Pourjafar,Massoud Saidijam,Michaela Miehe,Rezvan Najafi,Meysam Soleimani,Edzard Spillner
Breast cancer (BC) treatment has traditionally been challenging due to tumor heterogeneity. Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges by targeting multiple specific epitopes. In the current study, we designed a new bsAb against the most common BC cell surface proteins (SPs). To achieve this, we analyzed RNA-sequencing data to identify differentially expressed
-
Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study. J. Immunother. (IF 3.9) Pub Date : 2023-07-19 Junyu Huo,Xinyi Fan,Wei Sun,Peng Sun
Prognostic signatures related to the efficacy of immunotherapy have not been determined in gastric cancer (GC). We identified the differentially expressed genes between the CR/PR and SD/PD groups with the R package "limma" (false discovery rate <0.05) in the IMvigor210 data set. The GSE13861 (n=65), GSE15459 (n=192), GSE26899 (n=93), GSE26901 (n=109), GSE28541 (n=40), GSE34942 (n=56), and GSE62254
-
Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Immunother. (IF 3.9) Pub Date : 2023-06-21 Zhao Jin,Minghe Zhao
Programmed death 1 (PD-1) inhibitors have emerged as the new standard of care for the second-line treatment of advanced esophageal squamous cell carcinoma. There have been lots of research lately concerning the topic. A comprehensive assessment of the efficacy and safety profile between PD-1 inhibitors and chemotherapy is warranted. Hence, we carried out a systematic review and meta-analysis to illustrate
-
Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels. J. Immunother. (IF 3.9) Pub Date : 2023-06-19 Ni Zhao,Aimin Jiang,Xiao Shang,Fumei Zhao,Ruoxuan Wang,Xiao Fu,Zhiping Ruan,Xuan Liang,Tao Tian,Yu Yao,Chunli Li
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer therapy. This study aimed to develop novel risk classifiers to predict the risk of immune-related adverse events (irAEs) and the probability of clinical benefits. Patients with cancer who received ICIs from the First Affiliated Hospital of Xi 'an Jiaotong University from November 2020 to October 2022 were recruited
-
Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases. J. Immunother. (IF 3.9) Pub Date : 2023-06-19 Marion Gra,Anne Pham-Ledard,Emilie Gerard,Caroline Dutriaux,Marie Beylot-Barry,Fanny Duval,Louis Carla,Antoine Soulages,Sorilla Prey
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cutaneous tumor with high metastatic potential. In rare cases, it can be associated with paraneoplastic syndromes (PNS), which result from an antitumor immunity against antigens produced by the tumor itself. Lambert-Eaton Myasthenic Syndrome (LEMS) is a neurological autoimmune PNS characterized by an impairment of the neuromuscular junction
-
Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab. J. Immunother. (IF 3.9) Pub Date : 2023-05-26 Ye Huang,Farid Khan,Nehali V Saraiya,Omar S Punjabi,Vikas Gulati,Alan R Erickson,Steven Yeh
Checkpoint inhibition targeting programmed cell-death protein 1 has demonstrated efficacy for a wide range of indications including cutaneous malignancy. However, immune-related adverse events (irAEs), including infrequent but visually impactful ocular irAEs, require careful consideration of treatment options, including medication withdrawal, local corticosteroids, or rarely immunomodulation. This
-
Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations. J. Immunother. (IF 3.9) Pub Date : 2023-05-24 Liuchao Zhang,Lei Cao,Shuang Li,Liuying Wang,Yongzhen Song,Yue Huang,Zhenyi Xu,Jia He,Meng Wang,Kang Li
Only 30-40% of advanced melanoma patients respond effectively to immunotherapy in clinical practice, so it is necessary to accurately identify the response of patients to immunotherapy pre-clinically. Here, we develop KP-NET, a deep learning model that is sparse on KEGG pathways, and combine it with transfer- learning to accurately predict the response of advanced melanomas to immunotherapy using KEGG
-
Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy. J. Immunother. (IF 3.9) Pub Date : 2023-05-24 Peng Song,Dilinaer Wusiman,Wenbin Li,Lei Guo,Jianming Ying,Shugeng Gao,Jie He
Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death worldwide. Tumor-associated macrophages play pivotal roles in the tumor microenvironment (TME) and prognosis of LUAD. We first used single-cell RNA sequencing data to identify macrophage marker genes in LUAD. Univariate, least absolute shrinkage and selection operator and stepwise multivariate Cox regression analyses were conducted
-
Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion. J. Immunother. (IF 3.9) Pub Date : 2023-05-23 Sjoerd Kramer,Koen van Hee,Hans Blokzijl,Frans van der Heide,Marijn C Visschedijk
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, but are associated with serious adverse events like pancreatitis. Current guidelines are limited to the first step in treating acute ICI-related pancreatitis with steroids but lack treatment advices for steroid dependent pancreatitis. We describe a case series of 3 patients who developed ICI-related pancreatitis
-
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J. Immunother. (IF 3.9) Pub Date : 2023-05-23 Thi Thuy Nguyen,Nguyen Thanh Nhu,Van Khoi Tran,Nguyen Van Cau,Chiou-Feng Lin
Treatment with chemoimmunotherapy (CIT) is considered an appropriate front-line treatment option for chronic lymphocytic leukemia (CLL). However, outcomes remain suboptimal. Bruton tyrosine kinase inhibitor (BTKi) combined with anti-CD20 antibody is an effective treatment for treatment-naïve, relapsed/refractory CLL patients. A systematic review and meta-analysis of randomized controlled trials was
-
Fecal Microbiota Transplantation for Immune Checkpoint Inhibitor-Induced Colitis Is Safe and Contributes to Recovery: Two Case Reports. J. Immunother. (IF 3.9) Pub Date : 2023-05-23 Bas Groenewegen,Elisabeth M Terveer,Arjen Joosse,Marieke C Barnhoorn,Romy D Zwittink
Immune checkpoint inhibitors (ICIs) have improved the prognosis in multiple cancer types. However, ICIs can induce immune-related adverse events such as immune-mediated enterocolitis (IMC). The gut microbiota may be implicated in IMC development. Therefore, we investigated fecal microbiota transplantation (FMT) as a treatment option for 2 patients with metastatic cancer suffering from refractory IMC
-
Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy. J. Immunother. (IF 3.9) Pub Date : 2023-05-22 Liang Wen,Jianhui Zhao,Yixiao Yang,Wen Chen,Yingying Bao,Jian Zhang,Tao Wei,Lijuan Zhou,Bin Xi,Yun Zhang,Tingbo Liang
Immune checkpoint blockades have been widely used to treat various malignancies. Programmed cell death protein 1 (PD-1) inhibitor-induced alopecia areata, one of the immune-related adverse events, is rarely reported. We present a case of alopecia universalis during the treatment of Sintilimab, a monoclonal anti-PD-1 antibody, in a patient with hepatocellular carcinoma. A 65-year-old male was diagnosed
-
Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study J. Immunother. (IF 3.9) Pub Date : 2023-05-16 Wen You, Xinyu Liu, Hao Tang, Bo Lu, Qingyang Zhou, Yue Li, Minjiang Chen, Jing Zhao, Yan Xu, Mengzhao Wang, Jiaming Qian, Bei Tan
Vitamin D (VitD) is potentially immunomodulatory, so here we aimed to explore the relationships between serum VitD levels, immune checkpoint inhibitor (ICI) efficacy, and immune-related adverse events (irAEs). Serum 25-hydroxyvitamin D [25(OH)D] levels were quantified before and after ICI treatment in prospectively enrolled patients with advanced lung cancers. Of 77 enrolled patients, 29 developed
-
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy J. Immunother. (IF 3.9) Pub Date : 2023-05-01 Elizabeth I. Buchbinder, Kathleen L. Pfaff, Madison M. Turner, Michael Manos, Olivia Ouyang, Patrick A. Ott, Anita Giobbie-Hurder, Scott J. Rodig, F. Stephen Hodi
Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was
-
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Michiel C.T. van Zeijl, Jesper van Breeschoten, Liesbeth C. de Wreede, Michel W.J.M. Wouters, Doranne L. Hilarius, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Karijn P
In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3–4 adverse events. Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma. Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021
-
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Huandi Ding, Bing Yao, Lei Ci, Jing Feng, Pingkai Ouyang, Guoguang Chen, Xiwu Hui, Demin Zhou
Siglec-15, an inhibitory immune checkpoint, is an emerging target in cancer immunotherapy. Blocking the function of Siglec-15 is an excellent strategy for cancer treatment and antibody blockade has been used to target Siglec-15. However, whether Fc-mediated effector functions contribute to the therapeutic effect of antibodies remains unclear. Herein, we generated a monoclonal antibody, 1-15D1, which
-
TLR Agonist Therapy of Metastatic Breast Cancer in Mice J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Dennis M. Klinman, Emilie Goguet, Debra Tross
Toll-like receptor (TLR) 7/8 and 9 agonists stimulate an innate immune response that supports the development of tumor-specific immunity. Previous studies showed that either agonist individually could cure mice of small tumors and that when used in combination, they could prevent the progression of larger tumors (>300 mm3). To examine whether these agents combined could control metastatic disease,
-
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions. J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Huandi Ding,Bing Yao,Lei Ci,Jing Feng,Pingkai Ouyang,Guoguang Chen,Xiwu Hui,Demin Zhou
Siglec-15, an inhibitory immune checkpoint, is an emerging target in cancer immunotherapy. Blocking the function of Siglec-15 is an excellent strategy for cancer treatment and antibody blockade has been used to target Siglec-15. However, whether Fc-mediated effector functions contribute to the therapeutic effect of antibodies remains unclear. Herein, we generated a monoclonal antibody, 1-15D1, which
-
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Michiel C T van Zeijl,Jesper van Breeschoten,Liesbeth C de Wreede,Michel W J M Wouters,Doranne L Hilarius,Christian U Blank,Maureen J B Aarts,Franchette W P J van den Berkmortel,Jan Willem B de Groot,Geke A P Hospers,Ellen Kapiteijn,Djura Piersma,Rozemarijn S van Rijn,Marion A Stevense-den Boer,Astrid A M van der Veldt,Gerard Vreugdenhil,Marye J Boers-Sonderen,Karijn P M Suijkerbuijk,John B A G Haanen
In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma. Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021
-
TLR Agonist Therapy of Metastatic Breast Cancer in Mice. J. Immunother. (IF 3.9) Pub Date : 2023-04-28 Dennis M Klinman,Emilie Goguet,Debra Tross
Toll-like receptor (TLR) 7/8 and 9 agonists stimulate an innate immune response that supports the development of tumor-specific immunity. Previous studies showed that either agonist individually could cure mice of small tumors and that when used in combination, they could prevent the progression of larger tumors (>300 mm 3 ). To examine whether these agents combined could control metastatic disease
-
Tumor Microenvironment CD8 T and Treg Cells–related Genes Signature Distinguishes Distinct Prognosis and Targeted Therapies Response in Endometrial Cancer J. Immunother. (IF 3.9) Pub Date : 2023-04-27 Xiaodie Liu, Dingqing Feng, Wenhui Wang, Jing Liang, Huan Yu, Bin Ling
Although most endometrial cancer (EC) patients have a favorable prognosis, the overall survival (OS) of metastatic and recurrent EC could hardly be improved by the current chemoradiotherapy. We aimed to reveal the tumor microenvironment immune infiltration characteristics to elucidate the underlying mechanism of EC progression and guide clinical decisions. In the Cancer Genome Atlas (TCGA) cohort,
-
Tumor Microenvironment CD8 T and Treg Cells-related Genes Signature Distinguishes Distinct Prognosis and Targeted Therapies Response in Endometrial Cancer. J. Immunother. (IF 3.9) Pub Date : 2023-04-27 Xiaodie Liu,Dingqing Feng,Wenhui Wang,Jing Liang,Huan Yu,Bin Ling
Although most endometrial cancer (EC) patients have a favorable prognosis, the overall survival (OS) of metastatic and recurrent EC could hardly be improved by the current chemoradiotherapy. We aimed to reveal the tumor microenvironment immune infiltration characteristics to elucidate the underlying mechanism of EC progression and guide clinical decisions. In the Cancer Genome Atlas (TCGA) cohort,
-
A Novel Fc-Engineered Anti-HER2 Bispecific Antibody With Enhanced Antitumor Activity J. Immunother. (IF 3.9) Pub Date : 2023-05-01 Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Fatemeh Torkashvand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Fazel Shokri, Mohammad Mehdi Amiri
Human epidermal growth factor receptor 2 (HER2) overexpression has been demonstrated in a variety of cancers. Targeted therapy with anti-HER2 monoclonal antibodies (mAbs) has been approved as a therapeutic modality. Despite the efficacy of mAbs in tumor treatment, many patients do not benefit from this therapeutic platform. Fragment crystallizable (Fc) engineering is a common approach to improve the
-
Enhancing Efficacy of TCR-engineered CD4+ T Cells Via Coexpression of CD8α J. Immunother. (IF 3.9) Pub Date : 2023-05-01 Victoria E. Anderson, Sara S. Brilha, Anika M. Weber, Annette Pachnio, Guy E. Wiedermann, Sumaya Dauleh, Tina Ahmed, George R. Pope, Laura L. Quinn, Roslin Y. Docta, Adriano Quattrini, Siobhan Masters, Neil Cartwright, Preetha Viswanathan, Luca Melchiori, Louise V. Rice, Alexandra Sevko, Claire Gueguen, Manoj Saini, Barbara Tavano, Rachel J.M. Abbott, Jonathan D. Silk, Bruno Laugel, Joseph P. Sanderson
Adoptive cell therapy with T cells expressing affinity-enhanced T-cell receptors (TCRs) is a promising treatment for solid tumors. Efforts are ongoing to further engineer these T cells to increase the depth and durability of clinical responses and broaden efficacy toward additional indications. In the present study, we investigated one such approach: T cells were transduced with a lentiviral vector
-
Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine J. Immunother. (IF 3.9) Pub Date : 2023-05-01 Ravi A. Madan, Jason M. Redman, Fatima Karzai, William L. Dahut, Lisa Cordes, Farhad Fakhrejahani, Tuyen Vu, Nadeem Sheikh, Jeffrey Schlom, James L. Gulley
Therapeutic cancer vaccines including sipuleucel-T, a prostatic acid phosphatase (PAP) targeted vaccine that improves survival in metastatic castration-resistant prostate cancer (mCRPC), can produce immune responses that translate to clinical benefit. The effects of sequential checkpoint inhibitors after therapeutic vaccine on immune responses are unknown. Avelumab is an anti–programmed death ligand-1
-
Subclinical Celiac Disease Unmasked by Immune Checkpoint Inhibitor Therapy J. Immunother. (IF 3.9) Pub Date : 2023-05-01 David S. Braun, Shruti Patel, Armond Schwartz
Immune checkpoint inhibitors (ICI) are antibodies that block immune checkpoint proteins from binding with their partner proteins on cancer cells, subsequently allowing cytotoxic T-cell-associated enhancement of antitumor responses. Although ICIs have become the standard of care for various malignancies, their use is often limited by unique immune-related adverse events, including dermatologic, endocrine
-
Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study J. Immunother. (IF 3.9) Pub Date : 2023-05-01 Shengming Jin, Zhi Shang, Wenwen Wang, Chengyuan Gu, Yu Wei, Yu Zhu, Chen Yang, Tiantian Zhang, Yao Zhu, Yiping Zhu, Junlong Wu, Dingwei Ye
Programmed cell death 1 ligand 1), programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3, lymphocyte activation gene-3, and T-cell immunoglobulin and ITIM domain (TIGIT) are considered major immune co-inhibitory receptors (CIRs) and the most promising immunotherapeutic targets in cancer treatment, but they are largely
-
COVID-19: Attacks Immune Cells and Interferences With Antigen Presentation Through MHC-Like Decoy System J. Immunother. (IF 3.9) Pub Date : 2023-04-01 Wenzhong Liu, Hualan Li
The high mortality of coronavirus disease 2019 is related to poor antigen presentation and lymphopenia. Cytomegalovirus and the herpes family encode a series of major histocompatibility complex (MHC)-like molecules required for targeted immune responses to achieve immune escape. In this present study, domain search results showed that many proteins of the severe acute respiratory syndrome coronavirus
-
Pembrolizumab-Induced Acral Vasculitis J. Immunother. (IF 3.9) Pub Date : 2023-04-01 Binoy Yohannan, Tate Truly, Jaya Kala, Syed Hasan Jafri
Immune checkpoint inhibitors (ICIs) have emerged as groundbreaking new therapies for a variety of solid tumors. ICIs stimulate the host immune system to attack cancer cells. However, this nonspecific immune activation can cause autoimmunity across multiple organ systems—this is referred to as an immune-related adverse event. Vasculitis secondary to ICI administration is an extremely rare event seen
-
Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of MUC1 for the Treatment of Intrahepatic Cholangiocarcinoma J. Immunother. (IF 3.9) Pub Date : 2023-04-01 Li Mao, Sheng Su, Jia Li, Songyang Yu, Yu Gong, Changzhou Chen, Zhiqiang Hu, Xiaowu Huang
Intrahepatic cholangiocarcinoma (ICC) is a common malignancy arising from the liver with limited 5-year survival. Thus, there is an urgency to explore new treatment methods. Chimeric antigen receptor T (CAR T) cell therapy is a very promising cancer treatment. Though, several groups have investigated CAR T cells targeting MUC1 in solid cancer models, Tn-MUC1-targeted CAR T cells have not yet to be
-
A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development J. Immunother. (IF 3.9) Pub Date : 2023-04-01 Jamison Grailer, Zhijie Jey Cheng, Jim Hartnett, Michael Slater, Frank Fan, Mei Cong
T-cell immunotherapies are promising strategies to generate T-cell responses towards tumor-derived or pathogen-derived antigens. Adoptive transfer of T cells genetically modified to express antigen receptor transgenes has shown promise for the treatment of cancer. However, the development of T-cell redirecting therapies relies on the use of primary immune cells and is hampered by the lack of easy-to-use
-
Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer J. Immunother. (IF 3.9) Pub Date : 2023-04-01 Tien-Hua Chen, Ming-Huang Chen, Yi-Ping Hung, Nai-Jung Chiang, Kuo-Hung Huang, Yi-Hsiang Lin, Ryan Weihsiang Lin, Yee Chao, Anna Fen-Yau Li, Hung-Yuan Yu, Hsuen-En Hwang, Yi-Chen Yeh, Yu-Chao Wang, Wen-Liang Fang
Immunotherapy in combination with chemotherapy is the current treatment of choice for frontline programmed cell death ligand 1 (PD-L1)–positive gastric cancer. However, the best treatment strategy remains an unmet medical need for elderly or fragile patients with gastric cancer. Previous studies have revealed that PD-L1 expression, Epstein-Barr virus association, and microsatellite instability-high
-
Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of MUC1 for the Treatment of Intrahepatic Cholangiocarcinoma. J. Immunother. (IF 3.9) Pub Date : 2023-03-08 Li Mao,Sheng Su,Jia Li,Songyang Yu,Yu Gong,Changzhou Chen,Zhiqiang Hu,Xiaowu Huang
Intrahepatic cholangiocarcinoma (ICC) is a common malignancy arising from the liver with limited 5-year survival. Thus, there is an urgency to explore new treatment methods. Chimeric antigen receptor T (CAR T) cell therapy is a very promising cancer treatment. Though, several groups have investigated CAR T cells targeting MUC1 in solid cancer models, Tn-MUC1-targeted CAR T cells have not yet to be
-
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α. J. Immunother. (IF 3.9) Pub Date : 2023-02-27 Victoria E Anderson,Sara S Brilha,Anika M Weber,Annette Pachnio,Guy E Wiedermann,Sumaya Dauleh,Tina Ahmed,George R Pope,Laura L Quinn,Roslin Y Docta,Adriano Quattrini,Siobhan Masters,Neil Cartwright,Preetha Viswanathan,Luca Melchiori,Louise V Rice,Alexandra Sevko,Claire Gueguen,Manoj Saini,Barbara Tavano,Rachel J M Abbott,Jonathan D Silk,Bruno Laugel,Joseph P Sanderson,Andrew B Gerry
Adoptive cell therapy with T cells expressing affinity-enhanced T-cell receptors (TCRs) is a promising treatment for solid tumors. Efforts are ongoing to further engineer these T cells to increase the depth and durability of clinical responses and broaden efficacy toward additional indications. In the present study, we investigated one such approach: T cells were transduced with a lentiviral vector
-
Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. J. Immunother. (IF 3.9) Pub Date : 2023-02-24 Ravi A Madan,Jason M Redman,Fatima Karzai,William L Dahut,Lisa Cordes,Farhad Fakhrejahani,Tuyen Vu,Nadeem Sheikh,Jeffrey Schlom,James L Gulley
Therapeutic cancer vaccines including sipuleucel- T , a prostatic acid phosphatase (PAP) targeted vaccine that improves survival in metastatic castration-resistant prostate cancer (mCRPC), can produce immune responses that translate to clinical benefit. The effects of sequential checkpoint inhibitors after therapeutic vaccine on immune responses are unknown. Avelumab is an anti-programmed death ligand-1
-
COVID-19: Attacks Immune Cells and Interferences With Antigen Presentation Through MHC-Like Decoy System. J. Immunother. (IF 3.9) Pub Date : 2023-02-20 Wenzhong Liu,Hualan Li
The high mortality of coronavirus disease 2019 is related to poor antigen presentation and lymphopenia. Cytomegalovirus and the herpes family encode a series of major histocompatibility complex (MHC)-like molecules required for targeted immune responses to achieve immune escape. In this present study, domain search results showed that many proteins of the severe acute respiratory syndrome coronavirus
-
Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4+ Th1 Response in Metastatic Non–Small Cell Lung Cancer J. Immunother. (IF 3.9) Pub Date : 2023-02-20 Mylène Wespiser, Amélie Marguier, Benoît Lecoester, Thibault Richard, Laura Boullerot, Marine Malfroy, Abhishek Kumar, Caroline Laheurte, Olivier Adotévi
Limited data have reported the evolution of antitumor immune responses under chemoimmunotherapy (chemo-IO) in patients with metastatic non–small cell lung cancer. In this concise study, we performed dynamic monitoring of antitumor CD4+ T helper 1 (Th1) response in peripheral blood from 12 patients receiving a first-line chemo-IO. Tumor-reactive CD4+ Th1 cells were assessed within blood lymphocytes
-
Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants J. Immunother. (IF 3.9) Pub Date : 2023-02-01 Qing Wu, Chunlan Wu, Xianhe Xie
The project was designed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs) in triple-negative breast cancer (TNBC). Electronic databases were screened to identify relevant trials. The primary endpoints were prognostic parameters and adverse events (AEs) through pooled rate, odds ratio, and hazard ratio (HR) with 95% CI. Totally, 6558 TNBC patients from 41 cohorts were included
-
Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis J. Immunother. (IF 3.9) Pub Date : 2023-02-01 Ruiyi Deng, Hua Zhang, Yuan Li, Yanyan Shi
The influence of antacids use on immune checkpoint inhibitor (ICI) efficacy remains unclear. A systematic review and meta-analysis was performed to evaluate the effect of proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) on ICI efficacy in advanced solid cancer patients. A systematic literature search in PubMed, EMBASE, and Web of Science was performed to retrieve studies investigating
-
Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma J. Immunother. (IF 3.9) Pub Date : 2023-02-01 Anna Bold, Johannes Gaertner, Alexander Bott, Volker Mordstein, Kerstin Schaefer-Eckart, Martin Wilhelm
The transformation of chronic lymphocytic leukemia to an aggressive lymphoma, called Richter transformation, is often accompanied by resistance to chemotherapy and high mortality. Thus, novel therapeutic strategies are required for the successful treatment of these patients. One possibility is cellular immunotherapy with chimeric antigen receptor T cells. However, the time delay until cells are available
-
Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature J. Immunother. (IF 3.9) Pub Date : 2023-02-01 Charlotte Emonet, Florence Tétart, Olivia Bauvin, Lucie Cellier, Philippe Courville, Claire Mignard, Raphaël Janela-Lapert, Alexis Lefebvre, Samy Lachkar, Diane Lechevalier, Laurence Lagarce, Priscille Carvalho, Billal Tedbirt
Immune checkpoint inhibitors (ICIs) have become the standard treatment for many types of cancer. After several years of using these therapies, many adverse events related to ICIs have been observed. Dermatologic toxicities such as nonspecific morbilliform rash, vitiligo, Stevens-Johnson syndrome/toxic epidermal necrolysis, and more rarely, lichenoid eruptions have been described in the literature.
-
Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer J. Immunother. (IF 3.9) Pub Date : 2023-02-01 Peixin Tan, Wei Huang, Xinyan He, Fengquan Lv, Yanhai Cui, Shasha Du
Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical data of 60 patients with lung cancer who developed CIP. Refractory CIP was defined as CIP with poor response
-
The Combination of TIM3-Based Checkpoint Blockade and Oncolytic Virotherapy Regresses Established Solid Tumors J. Immunother. (IF 3.9) Pub Date : 2023-01-01 Cody C. Gowan, Mee Y. Bartee, Erica Flores, Bulent A. Aksoy, Conor Templeton, Kati Baillie, Myroslawa Happe, Eric Bartee
T-cell immunoglobulin and mucin domain 3 (TIM3) is emerging as a potential target for antibody-based checkpoint blockade. However, the efficacy of TIM3 blockade in combination with other treatment modalities, has not been extensively studied. In the current work we combined TIM3 blockade with myxoma virus-based oncolytic virotherapy (OV). Our results demonstrate that myxoma virus’s ability to initiate
-
Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells J. Immunother. (IF 3.9) Pub Date : 2023-01-01 Justin C. Boucher, Bin Yu, Gongbo Li, Bishwas Shrestha, David Sallman, Ana Marie Landin, Cheryl Cox, Kumar Karyampudi, Claudio Anasetti, Marco L. Davila, Nelli Bejanyan
Higher γδ T cell counts in patients with malignancies are associated with better survival. However, γδ T cells are rare in the blood and functionally impaired in patients with malignancies. Promising results are reported on the treatment of various malignancies with in vivo expansion of autologous γδ T cells using zoledronic acid (zol) and interleukin-2 (IL-2). Here we demonstrated that zol and IL-2
-
The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation J. Immunother. (IF 3.9) Pub Date : 2023-01-01 Saber A. Amin, Michael J. Baine, Ibur Rahman, Chi Lin
Immunotherapy has been approved for stage III non-small cell lung cancer (NSCLC) as consolidation therapy after chemoradiation in patients whose disease does not progress after chemoradiation. However, many patients do not receive chemoradiation due to either the drugs’ side effects or poor performance status. This study’s objective is to investigate the association of immunotherapy combined with chemotherapy
-
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication J. Immunother. (IF 3.9) Pub Date : 2023-01-01 Sebastiano Buti, Umberto Basso, Diana Giannarelli, Ugo De Giorgi, Marco Maruzzo, Roberto Iacovelli, Luca Galli, Camillo Porta, Francesco Carrozza, Giuseppe Procopio, Giuseppe Fonarini, Giovanni Lo Re, Matteo Santoni, Roberto Sabbatini, Antonio Cusmai, Paolo Andrea Zucali, Carlo Aschele, Editta Baldini, Elena Zafarana, Adolfo Favaretto, Silvana Leo, Alketa Hamzaj, Rosanna Mirabelli, Franco Nole’, Silvia
A concomitant drug-based score was developed by our group and externally validated for prognostic and predictive purposes in patients with advanced cancer treated with immune checkpoint inhibitors (ICIs). The model considers the use of three classes of drugs within a month before initiating ICI, assigning score 1 for each between proton pump inhibitor and antibiotic administration until a month before
-
Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature J. Immunother. (IF 3.9) Pub Date : 2023-01-01 Francisco Zambrana, Carmen Barbancho, Miriam Huelves, Belén García de Santiago, Yolanda Martín, Marta Muñoz de Lengaria, Guillermo de Velasco
Pregnancy and cancer share CTLA-4 and PD-1/PD-L1 as some of the immunomodulatory pathways that reshape the immune system from a destructive response to a state of tolerance to the fetus and the tumor, respectively. Ipilimumab (anti-CTLA-4 inhibitor) and nivolumab (anti-PD-1 inhibitor) are used in combination for the treatment of metastatic renal cell carcinoma, and their use could theoretically result